LAMP Human DPD4 Deficiency KIT (4 variants)
The LAMP Human DPD4var KIT is an in vitro diagnostic test intended for the qualitative detection of four different non-functional or less functional DPYD alleles (*2A, *13, c.2846A>T, c.1129-5923C>G) by Loop-mediated isothermal amplification (LAMP) on EDTA whole blood and extracted DNA. This assay is dedicated to professional use in diagnostic laboratories. The device is not for self-testing.
Regulatory Status: CE-IVDR
Format: 24 / 96 reactions
Target gene: DPYD
Drug relevance: Fluoropyrimidines, including drugs like 5-fluorouracil (5-FU), capecitabine, and tegafur
Variants detected: DPYD*2A (rs3918290), DPYD*13 (rs55886062), DPYD rs67376798, DPYD rs75017182
Method: LAMP + meting curve analysis
Sample: EDTA whole blood - no DNA extraction required - or extracted DNA
Compatible instruments: LightCycler 480 I&II / Cobas z 480 (Roche); CFX96 / CFX Opus 96 (Bio-Rad); QuantStudio 1/3/5 & 6/7 Flex (Applied Biosystems); MIC qPCR (Bio Molecular Systems); LC-Genie III & Genie HT (Optigene)
Software / result interpretation: Automated genotype calling via GeneFox software; mandatory visual confirmation of the melting curve
Turn around time: < 1h
General information
Advantages
Related kits
The LC-DPD4var-LP kit uses loop mediated isothermal amplification, a robust amplification method using four to six primers per target, that can be directly used on EDTA-whole blood, without DNA purification and on extracted DNA samples from whole blood samples.
The genotyping is performed by melting curve analysis after amplification, using a specific probe and quencher for each target SNP.
Test principle
Fluoropyrimidines, including drugs like 5-fluorouracil (5-FU), capecitabine, and tegafur, are commonly prescribed to treat solid tumors. Approximately 10–40% of patients treated with fluoropyrimidines develop severe and potentially life-threatening side effects.
The dihydropyrimidine dehydrogenase (DPD) enzyme catalyzes the first and the rate-limiting step of the catabolic pathway of these drugs. Decreased DPD activity results in a slower drug clearance and extended half-life of 5-FU, which significantly increases the risk of dose-related toxicities.
DPD levels vary considerably between individuals, mainly due to differences in the DPYD gene. Among the Caucasian population, approximately 3-8% experience a partial DPD deficiency, while 0.3% show complete DPD deficiency.
Background information
https://www.annalsofoncology.org/article/S0923-7534(21)01277-1/fulltext
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00139/full
https://www.sciencedirect.com/science/article/pii/S2059702923000029
https://libstore.ugent.be/fulltxt/RUG01/003/146/807/RUG01-003146807_2023_0001_AC.pdf
Associated publications
You have a question regarding our products ? You want to know more about our method ?
Find out about our other expertises